JW Therapeutics Announces That Its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

jw-therapeutics

Share This Post

SHANGHAI, CHINA, November 9, 2022 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that as of November 8, 2022, its cell immunotherapy drugs (marketed products and candidate drugs included) have been successfully infused for treatment in 300 patients (clinical studies and commercialization included), bringing the hope of a cure for these patients and their families.

You may like to read: CAR T-Cell therapy in China

JW Therapeutics has built a world-class platform for technology and product development in cell immunotherapy, as well as a product pipeline covering both hematologic malignancies and solid tumors. The company has conducted or is conducting 9 clinical studies on hematologic malignancies and solid tumors. As the first product of JW Therapeutics and a CAR-T product approved as a Category 1 biologics product, relmacabtagene autoleucel injection (trade name: Carteyva®) was infused for treatment in the first patient in December 2017, and was approved by the China National Medical Products Administration in September 2021. This year, JW Therapeutics has also initiated clinical studies on solid tumors including advanced hepatocellular carcinoma.

James Li, co-founder, chairman, and CEO of JW Therapeutics, said, “Serving patients is the unswerving commitment of JW Therapeutics. We thank the regulators, investigators, healthcare professionals, business partners, and other forces who work with us to serve patients. We will continue to bring the hope of a cure for every patient by bringing in and developing more cutting-edge technologies, advancing the product pipeline, and reducing manufacturing costs.”

You may like to read: Cost of CAR T-Cell therapy in China

About Relmacabtagene Autoleucel Injection (trade name: Carteyva®)

Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, relma-cel has been approved by the China National Medical Products Administration (NMPA) for two indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, and the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review, and breakthrough therapy designations.

You may like to read: CAR T-Cell therapy for multiple myeloma in China

About JW Therapeutics

JW Therapeutics (HKEX: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, and is committed to becoming an innovation leader in cell immunotherapy. Founded in 2016, JW Therapeutics has built a world-class platform for product development in cell immunotherapy, as well as a product pipeline covering both hematologic malignancies and solid tumors. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and worldwide and leading the healthy and standardized development of China’s cell immunotherapy industry.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy